RAC1 activating mutations alone are insufficient to initiate carcinogenesis in skin, colorectal and lung cancer, but cooperation with BRAF or KRAS mutations results in enhanced proliferation and accelerated tumour growth [9,87,101,104,121]. Here, RAC1 is linked to lung carcinoma.